Thus, we examined the selective effects of anti-sCTLA-4 antibody blockade compared directly with anti-CTLA-4 mAb ipilimumab on supernatant effector cytokine levels from PBMC cell cultures provided by melanoma patient donors and stimulated with doses of plate-bound anti-CD3 mAb ranging from 0.02 to 1 μg/mL (Table 1 and Figure 6). The gene discussed is CTLA4; the disease is melanoma.